News

Rx.com Community Healthcare Network launches clinical services documentation platform to track MTM, CMR

BY Michael Johnsen

FORT WORTH, Texas — Rx.com Community Healthcare Network on Friday announced the release of the Care Rx application — a streamlined, patient-centric approach to clinical outcomes. Care Rx serves as a complete clinical services documentation platform for patient-focused medication therapy management, clinical disease management results and wellness programs. 
 
“The best feature of Care Rx is its flexibility. You can use your own custom MTM program if a local health plan requires it for network access or you can use one supplied by PDX,” said PDX CEO Jeff Farris. “Also, gaining momentum in the market is the push to provide accessible healthcare professionals that can offer patient services in convenient locations. We believe Care Rx equips pharmacists with a flexible clinical services platform necessary to remain competitive in this outcomes-based environment.”
 
With the Care Rx application, pharmacies are now able to collect data, perform MTM sessions, track medication adherence, perform Comprehensive Medication Reviews, execute high-touch specialty drug clinical programs, enter lab results, record activities such as vaccinations, and give pharmacists the opportunity to collaborate with patients in wellness programs. Care Rx also provides Rx.com Performance Network participants the opportunity to perform Manufacturer-provided MTM questions, modules and sessions that focus on the patient, drug and disease. 
 
Care Rx is integrated with PDX’s Enterprise Pharmacy System, the Community Pharmacy System and the PDX Classic system and is available via a secure sign-on from any web browser. When the Care Rx application is enabled within one of the compatible systems, pharmacists log in via the Patient Information page in which patient identification and triggers can be established to identify MTM opportunities. 
 
Integrated with the Rx.com Electronic Pharmacy Record, Care Rx facilitates the real-time aggregation of clinical data into a patient’s EHR. Data collected through MTM sessions — including any standardized records as well as lab results — become part of the patient’s clinical view. This data—along with prescription data—provides a comprehensive view of a patient’s overall health care status.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
News

Mylan, Gilead partner to expand access to hepatitis C treatments

BY Ryan Chavis

PITTSBURGH and HYDERABAD, India — Mylan announced that its subsidiary, Mylan Labs Limited, has signed an agreement with Gilead Science under which Mylan has been licensed the non-exclusive rights to manufacture and distribute sofosbuvir and the investigational single-tablet regimen of ledipasvir/sofosbuvir in 91 developing countries. Sofosbuvir is marketed by Gilead under the name Sovaldi. 
 
The countries that fall within the terms of the agreement account for more than 100 million people living with hepatitis C. Mylan will receive a technology transfer allowing it to manufacture low-cost versions of the medicines, the company stated. 
 
"Hepatitis C is a growing public health problem in developing countries, with Central and East Asia and North Africa among the regions most affected by this disease," Mylan CEO Heather Bresch said. "Unfortunately, patients in these regions often lack access to critical and effective treatments. This agreement with Gilead will allow Mylan to provide early access to a more affordable version of Sovaldi, helping to meet the unmet medical needs of the millions of patients in developing countries who do not currently have access to this life-saving medicine."
 
Sofosbuvir was approved by the Food and Drug Administration in December 2013. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
News

Sharps Compliance, MedReturn announce retail solution to collecting expired medicines per DEA guidelines

BY Michael Johnsen

HOUSTON — Sharps Compliance Corp. and MedReturn on Monday announced that they have joined forces to launch MedSafe, a patent-pending solution for the safe collection, transportation and proper disposal of unwanted and expired prescription medications, including controlled substances.
 
The MedSafe system is designed to meet or exceed the requirements of the new regulations issued by the Drug Enforcement Administration implementing the Secure and Responsible Drug Disposal Act of 2010, which becomes effective Oct. 9. The MedSafe system is a safe, cost-effective and operationally efficient system designed for long-term care facilities, pharmacies, local law enforcement, narcotic treatment programs, hospitals and clinics with onsite pharmacies.
 
The MedSafe solution consists of a collection receptacle manufactured by MedReturn, coupled with Sharps Compliance’s return logistics system and onsite disposal via incineration, the DEA and Environmental Protection Agency recommended method for disposal of medications. MedReturn is the leading manufacturer of drug collection units utilized by licensed law enforcement and is currently being used in 49 states.
 
“The MedSafe system [facilitates] the collection of both non-controlled and controlled substances in a standard, safe and cost-effective manner," said David Tusa, president and CEO Sharps Compliance. "[W]e believe the MedSafe solutions will save our healthcare customers money and create much needed operational efficiencies when compared to traditional methods of disposing of dispensed controlled substances," he said. “The MedSafe system also facilitates collection of unused and unwanted consumer medications including controlled substances at participating retail pharmacies. This will provide consumers with a convenient method of unused medication disposal while ridding homes and medicine cabinets of potentially harmful drugs. We believe the retail pharmacies will see the MedSafe system as a value added service that could be offered to their customers and patients while driving foot traffic.”
 
Each MedSafe unit is tested under the standards established by Underwriters Laboratories, has a tamper-proof, one-way drop and comes with a removable serialized and trackable inner liner for safe transportation and disposal. Access to the inner liner is protected by a double-locked door until removal by authorized personnel. Inner liners returned to the Sharps Compliance disposal facility will be processed and treated via incineration, leaving the medication non-retrievable as required by the Act. The 18-gallon MedSafe unit is designed for lower volume locations such as a long term care facility. The 38-gallon MedSafe unit is designed for collection sites with larger volumes such as a retail pharmacy.
 
In addition to a collection receptacle, the Act authorizes the use of a mailback solution for the proper disposal, transportation and treatment of unused medications including controlled substances. The mailback would be designed for use in the long-term care (on behalf of their patient), hospice and consumer markets.
 
“We are also working with the United States Postal Service to convert our existing TakeAway Environmental Return System solution such that it meets the requirements of the new DEA rules thereby allowing the collection, transportation and destruction of unused medications including controlled substances," Tusa said. "We have sold well over one million of our current TakeAway Environmental Return System solutions over the past five years and believe we are well-positioned to be a leader in the sale of the new mailback solutions designed to meet the new DEA rules.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?